GlassScriptPhysician profile
Gregg Kaiser
NPI 1386627925
$4,178.27
in general payments reported to CMS, 2019-2025
17 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $346 · 2021: $771 · 2022: $1,233 · 2023: $289 · 2024: $373 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $2,121.33 | 2019-2022 | |
| Genentech USA, INC. | $544.71 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $335.41 | 2019-2025 | Eylea, Eylea Hd |
| Apellis Pharmaceuticals, INC. | $258.70 | 2022-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $189.45 | 2023-2025 | Xipere, Visudyne |
| Astellas Pharma US INC | $177.15 | 2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $137.87 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $89.85 | 2019-2021 | |
| Alimera Sciences, INC. | $76.91 | 2019-2024 | Yutiq, Iluvien |
| Ani Pharmaceuticals, INC. | $59.47 | 2025 | Iluvien, Purified Cortrophin Gel |
| Allergan, INC. | $46.47 | 2019 | |
| Abbvie INC. | $42.95 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $38.33 | 2019 | |
| Shire North American Group INC | $30.04 | 2019 | |
| Dutch Ophthalmic, USA | $29.63 | 2024 | Eva, Combined Machine, Tissueblue |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$78,085.07 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregg Kaiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.